Atorvastatin-induced activation of Alzheimer's α secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding

Journal of Neurochemistry

Volumn 90, Issue 4, 2004, Pages 1005-1010

  Parvathy, S ^a   Ehrlich, Michelle ^a   Pedrini, Steve ^a   Diaz, Nichole ^b   Refolo, Lorenzo ^c   Buxbaum, Joseph D ^d   Bogush, Alexey ^a   Petanceska, Suzana ^b,e   Gandy, Sam ^a,f  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c Alzheimers Drug Discovery Foundation   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Amyloidogenic; Ectodomain shedding; Protein kinase; Proteomics; Secretase; Statin

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; ATORVASTATIN; CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ENZYME ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEOMICS; SIGNAL TRANSDUCTION;

AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; ENZYME ACTIVATION; ENZYME ACTIVATORS; ENZYME INHIBITORS; GENES, DOMINANT; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEUROBLASTOMA; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PYRROLES;

ANIMALIA;

EID: 4143063543     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02521.x     Document Type: Article

References (28)

1. Brookmeyer R., Gray S. and Kawas C. (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 1337-1342.
2. Buxbaum J. D., Gandy S. E., Cicchetti P., Ehrlich M. E., Czernik A. J., Fracasso R. P., Ramabhadran T. V., Unterbeck A. J. and Greengard P. (1990) Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc. Natl Acad. Sci. USA 87, 6003-6006.
3. Buxbaum J. D., Oishi M., Chen H. I., Pinkas-Kramarski R., Jaffe E. A., Gandy S. E. and Greengard P. (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl Acad. Sci. USA 89, 10075-10078.
4. Buxbaum J. D., Koo E. H. and Greengard P. (1993) Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc. Natl Acad. Sci. USA 90, 9195-9198.
5. Buxbaum J. D., Geoghagen N. S. and Friedhoff L. T. (2001) Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J. Alzheimers Dis. 3, 221-229.
6. Caporaso G. L., Gandy S. E., Buxbaum J. D., Ramabhadran T. V. and Greengard P. (1992) Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein. Proc. Natl Acad. Sci. USA 89, 3055-3059.
7. Desdouits-Magnen J., Desdouits F., Takeda S., Syu L. J., Saltiel A. R., Buxbaum J. D., Czemik A. J., Nairn A. C. and Greengard P. (1998) Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J. Neurochem. 70, 524-530.
8. Ehehalt R., Keller P., Haass C., Thiele C. and Simons K. (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113-123.
9. Eto M., Kozai T., Cosentino F., Joch H. and Luscher T. F. (2002) Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105, 1756-1759.
10. Fassbender K., Simons M., Bergmann C. et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 5856-5861.
11. Gandy S., Martins R. N. and Buxbaum J. (2004) Molecular and cellular basis for anti-amyloid therapy in Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 17, 259-266.
12. Gianni D., Zambrano N., Bimonte M., Minopoli G., Mercken L., Talamo F., Scaloni A. and Russo T. (2003) Platelet-derived growth factor induces the beta-gamma secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway. J. Biol. Chem. 278, 9290-9297.
13. Gillespie S. L., Golde T. E. and Younkin S. G. (1992) Secretory processing of the Alzheimer amyloid beta/A4 protein precursor is increased by protein phosphorylation. Biochem. Biophys. Res. Commun. 187, 1285-1290.
14. Ikezu T., Trapp B. D., Song K. S., Schlegel A., Lisanti M. P. and Okamoto T. (1998) Caveolae, plasma membrane microdomains for alpha-secretase mediated processing of the amyloid precursor protein. J. Biol. Chem. 273, 10485-10495.
15. Kojro E., Gimpl G., Lammich S., Marz W. and Fahrenholz F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl Acad. Sci. USA 98, 5815-5820.
16. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D. J., Sessa W. C. and Walsh K. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004-1010.
17. Langan T. J. and Volpe J. J. (1987) Cell cycle-specific requirement for mevalonate, but not for cholesterol, for DNA synthesis in glial primary cultures. J. Neurochem. 49, 513-521.
18. Mills J., Laurent Charest D., Lam F., Beyreuther K., Ida N., Pelech S. L. and Reiner P. B. (1997) Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J. Neurosci. 17, 9415-9422.
19. Parvathy S., Hussain I., Karran E. H., Turner A. J. and Hooper N. M. (1999) Cleavage of Alzheimer's amyloid precursor protein by alpha-secretase occurs at the surface of neuronal cells. Biochemistry 38, 9728-9734.
20. Petanceska S. S. and Gandy S. (1999) The phosphatidylinositol-3-kinase inhibitor wortmannin alters the metabolism of the Alzheimer's amyloid precursor protein. J. Neurochem. 73, 2316-2320.
21. Petanceska S. S., DeRosa S., Olm V., Diaz N., Sharma A., Thomas-Bryant T., Duff K., Pappolla M. and Refolo L. M. (2002) Statin therapy for Alzheimer's disease: will it work? J. Mol. Neurosci. 19, 155-161.
22. Phiel C. J., Wilson C. A., Lee V. M. and Klein P. S. (2003) GSK3α regulates production of Alzheimer's disease amyloid beta peptides. Nature 423, 435-439.
23. Puglielli L., Konopka G., Pack-Chung E., Ingano L. A., Berezovska O., Hyman B. T., Chang T. Y., Tanzi R. E. and Kovacs D. M. (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3, 905-912.
24. Refolo L. M., Pappolla M. A., LaFrancois J. et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 890-899.
25. Skaletz-Rorowski A., Lutchman M., Kureishi Y., Lefer D. J., Faust J. R. and Walsh K. (2003) HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc. Res. 57, 253-264.
26. Stroppolo A., Guinea B., Tian C., Sommer J. and Ehrlich M. E. (2001) Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro. J. Neurochem. 79, 1027-1032.
27. Thinakaran G., Borchelt D. R., Lee M. K. et al. (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17, 181-190.
28. Wolozin B., Kellman W., Ruosseau P., Celesia G. G. and Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443.